CHU Amiens-Picardie
Salouël, 80480, France
NCT Number: NCT06821971
Uveitis is an inflammatory disease of the uvea, constituting the 4th leading cause of legal blindness worldwide and the 3rd leading cause of avoidable blindness . It is not a rare condition, with an incidence of 17 to 52 per 100,000 population and a prevalence of 38 to 204 per 100,000 population. In the case of cortico-dependence, it is generally accepted to propose sparing with a conventional immunosuppressant, whose efficacy is estimated at around 70%, compared with biotherapies, which are considered more effective (over 90%) but only available as 2nd-line treatment. However, there are few studies on the failure factors of this first-line treatment, such as macular thickness , gender, or vitamin D deficiency. Risk factors for flare-ups are nevertheless known, notably ethnicity, and smoking. The aim of this study is to identify risk factors for treatment failure after three months of first-line immunosuppressive therapy in patients with chronic non-infectious uveitis at Amiens-Picardie University Hospital.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Salouël, 80480, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 4 months
Therapeutic failure at 4 months following the initiation of a first-line immunosuppressant in patients with chronic non-infectious uveitis (CNIU).
Time frame: 9 months
Therapeutic failure at 9 months following the initiation of a first-line immunosuppressant in patients with chronic non-infectious uveitis (CNIU).
Centre Hospitalier Universitaire, Amiens
Other
Acronym: FAIL-UVEITIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04088409
Eye Diseases, Uveal Diseases
Le Kremlin-Bicêtre, France
View Trial DetailsNCT04704609
Eye Diseases, Uveal Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT06431373
Eye Diseases, Panuveitis
Phoenix, Arizona, United States
View Trial DetailsNCT07262437
Endophthalmitis, Eye Diseases
Milan, Italy
View Trial Details